Epredia 推出激光盒式打印机，旨在提高样品跟踪和实验室效率

。

Portsmouth, NH
November 1, 2024

Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE 6523), announces its SlideMateTM Laser slide printer has received an Innovative Technology designation for improving laboratory efficiency and sample traceability from Vizient, Inc., the largest healthcare provider performance improvement company in the country. Epredia exhibited SlideMate Laser at the Vizient Innovative Technology Exchange Sept. 18 in Las Vegas.

Each year, healthcare experts serving on Vizient provider-led councils review select products and technologies for their potential to enhance clinical care, patient safety, or healthcare worker safety or to improve business operations of healthcare organizations. Innovative Technology designations are awarded to previously contracted products to signal to healthcare providers the impact of these innovations on patient care and the business models of healthcare organizations.
Epredia’s SlideMate portfolio of slide printers is used in the cancer diagnostics process to identify and help track tissue samples. The company designed SlideMate Laser for clinical laboratories of any size looking to improve sample traceability. SlideMate Laser provides high-resolution, 600-dpi laser printing on microscope slides, enabling laboratories to include more identifying information directly on the tab of the slides that pathologists use in the cancer diagnostics workflow. This technology can embed up to 50 characters in a barcode on each slide, compared to 23 characters with traditional thermal transfer and ink jet technologies, improving both patient sample tracking and efficiency. 

SlideMate Laser also enhances laboratory efficiency by optimizing the slide movements through the printer and reducing potential downtime compared to thermal transfer and ink jet printers. Without the need to purchase, ink, bulbs or tape for slide printers, users can expect lower operational costs. With both on-demand and batch printing options, SlideMate Laser can integrate into a range of workflows. The laser printer’s software is easy to use and can be directly interfaced to a Laboratory Information System.

SlideMate Laser is the latest addition to Epredia’s world-class portfolio of precision cancer diagnostics products and services that provide a seamless end-to-end laboratory workflow. Epredia also offers the specialized slides designed for use with SlideMate Laser to help laboratories make a smooth transition to precision laser printing.

Steven Lynum, President of Epredia, said, “We set out to transform the anatomical pathology market with precision cancer diagnostics solutions. The Vizient Innovative Technology Designation is a true honor, and further proof that SlideMate Laser contributes to our goal of providing a seamless end-to-end laboratory workflow. Our team remains focused on improving patient outcomes by enabling pathologists to do their best work.”

“Congratulations to Epredia for achieving this peer-designated status,” said Kelly Flaharty, senior director contract services and Vizient Innovative Technology Program leader. “Our customer council deemed the SlideMate Laser worthy of this designation for its potential to make a real difference in the healthcare industry.”

Vizient represents a diverse customer base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute healthcare providers and has a portfolio that represents more than $140 billion in annual purchasing volume. Through its Innovative Technology Program, Vizient works with member-led councils and task forces to evaluate products for their potential to bring real innovation to healthcare. Vizient may award a contract to products deemed worthy of the Innovative Technology designation outside of the competitive bid cycle. 

关于 Epredia

Epredia是解剖病理学领域的全球领导者，为癌症精准诊断和组织诊断提供全面的解决方案。Epredia拥有Erie Scientific、Menzel-Gläser、Microm、Shandon和Richard-Allan Scientific等主要品牌，产品组合包括显微镜载玻片、仪器和耗材。Epredia 是 PHC Holdings 于 2019 年收购赛默飞世尔科技公司解剖病理学业务后成立的。Epredia在美国、英国、德国、瑞士和中国的主要基地开展业务，共有约1200名员工。Epredia 致力于通过提高全球患者的癌症诊断水平来实现改善生活的使命。欲了解有关 Epredia 及其产品的更多信息，请访问www.epredia.com。

中国医学科学院肿瘤医院

关于PHC控股公司（PHC集团）

PHC Holdings Corporation（东京证券交易所股票代码：6523）是一家全球性医疗保健公司，其使命是通过具有积极影响并能改善人们生活的医疗保健解决方案为社会健康做出贡献。其子公司（统称为 PHC 集团）包括 PHC Corporation、Epredia、Ascensia Diabetes Care、LSI Medience Corporation、Mediford 和 Wemex。这些公司共同开发、生产、销售和服务糖尿病管理、医疗保健解决方案、生命科学和诊断解决方案。PHC 集团 2022 财年的合并净销售额为 3,564 亿日元，产品和服务遍布全球 125 个国家。

欲了解更多信息，请联系：

Julia Cottrill
PHC 集团企业传讯部
电子邮件：julia.cottrill@phchd.com